Steven Shallcross | executive |
James Molloy | analyst |
Chad Yahn | analyst |
Manel Cascalló | executive |
Greetings, and welcome to the Theriva Biologics 2023 First Quarter Operational Highlights and Financial Results. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Chris Calabrese with LifeSci Advisors. Thank you, Chris.
You may begin.